Conventum - Alluvium Global Fund Q3 2026 Performance Update

The Fund declined 3.2% in EUR terms, 3.8% in USD and 4.2% in AUD during the quarter. It initiated a new position in Jack Henry, while shares of its two healthcare investments rose strongly after significant declines in the June quarter.

Analysis

The disclosure is more useful as a clue about portfolio construction than as a standalone signal: a newly initiated Jack Henry position may add exposure to bank technology budgets and long-duration vendor relationships, but without the thesis, position size, or valuation, it does not establish a compelling catalyst or expected return. The healthcare recovery is similarly ambiguous; after a prior drawdown, a strong quarter can reflect relief positioning rather than improved fundamentals. The fund’s returns in three currencies cannot be used to infer underlying performance or FX contribution without its base currency, hedging policy, and benchmark.

Near term, avoid extrapolating either the healthcare rebound or the new position into a performance inflection. Over 1–3 months, the useful evidence is whether Jack Henry’s reported bookings, recurring revenue, and guidance support the investment case, and whether healthcare holdings show earnings or clinical/regulatory progress rather than merely price recovery. Over 6–18 months, bank spending priorities and healthcare asset-level outcomes matter more than the novelty of the positions. The principal contrarian point is that a newly disclosed position can attract attention despite being too small to affect returns; conversely, the fund’s aggregate drawdown may conceal concentrated exposure or a thesis break. No trade is justified from this disclosure alone.

Key Decisions for Investors

• No immediate position: obtain Jack Henry’s portfolio weight, entry rationale, and valuation before treating the disclosure as a buy signal; use company name rather than inferring a ticker.
• Monitor Jack Henry’s next results for bookings, recurring-revenue trends, and guidance. A deterioration in these indicators would weaken the possible bank-technology thesis; absent confirmation, do not chase the new-position narrative.
• For the healthcare holdings, distinguish earnings, clinical, or regulatory catalysts from post-drawdown mean reversion. Reassess if the rebound is accompanied by weaker guidance or adverse asset-level news.
• Request attribution by security, sector, and currency, plus the fund’s benchmark and hedging policy. A concentration or FX mismatch could change the read-through; the reported multi-currency returns alone do not establish either.